CalciMedica (CALC) grants 65,124 stock options to President and COO

Rhea-AI Filing Summary

CalciMedica, Inc. reported that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036 and vests in monthly installments over four years, beginning April 1, 2026, after a Form S-8 is filed to cover shares added under the company’s 2023 Equity Incentive Plan evergreen provision.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dunn Michael J.

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	65,124	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 65,124 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 65,124 shares Exercise price: $0.585 per share Expiration date: April 4, 2036 +2 more

5 metrics

Option grant size 65,124 shares Employee stock option covering CalciMedica common stock

Exercise price $0.585 per share Strike price for the employee stock option

Expiration date April 4, 2036 Option term end date

Vesting start date April 1, 2026 Start of 1/48 monthly vesting schedule

Form S-8 condition Filing required before vesting No shares vest until Form S-8 covers 2026 evergreen shares

Key Terms

Employee Stock Option, Form S-8, 2023 Equity Incentive Plan, evergreen provision, +1 more

5 terms

Employee Stock Option financial

"security_title: "Employee Stock Option (Right to Buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Form S-8 regulatory

"no shares shall vest until the filing of the Company's registration statement on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

2023 Equity Incentive Plan financial

"shares authorized for issuance under the Company's 2023 Equity Incentive Plan"

evergreen provision financial

"automatically added to the shares authorized for issuance ... pursuant to an annual "evergreen" provision"

An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.

vesting financial

"1/48th of the shares subject to the option vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dunn Michael J.

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD. #202

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.585	04/05/2025		A		65,124		(1)	04/04/2036	Common Stock	65,124	$0	65,124	D

Explanation of Responses:

1. Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

	/s/ John Dunn, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CalciMedica (CALC) disclose for Michael J. Dunn?

CalciMedica disclosed that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed price.

What are the key terms of Michael J. Dunn’s CalciMedica (CALC) stock options?

The option covers 65,124 shares of CalciMedica common stock with an exercise price of $0.585 per share and expires on April 4, 2036. These terms define how many shares he may buy, at what price, and until when.

How and when do Michael J. Dunn’s CalciMedica (CALC) options vest?

Beginning April 1, 2026, one forty-eighth of the 65,124 option shares vest in equal monthly installments over four years. This gradual vesting schedule ties the award to continued service over time instead of granting full ownership immediately.

What condition affects vesting of Dunn’s CalciMedica (CALC) stock options?

No shares under the option will vest until CalciMedica files a Form S-8 covering common shares automatically added on January 1, 2026 under its 2023 Equity Incentive Plan. This filing is required before the vesting schedule can begin operating.

How many CalciMedica (CALC) options does Michael J. Dunn hold after this grant?

After this award, Michael J. Dunn holds 65,124 employee stock options directly, according to the filing. This figure reflects the full amount of the newly granted options and shows his potential future right to acquire an equivalent number of common shares.

Is Michael J. Dunn’s CalciMedica (CALC) option grant an open-market transaction?

No, the transaction is coded as a grant or award acquisition, not a market trade. It represents compensation in the form of employee stock options, giving Dunn the right to buy shares at $0.585, rather than a purchase or sale on the open market.